IM Cannabis (IMCC) Research & Development (2020 - 2021)
IM Cannabis (IMCC) recorded quarterly Research & Development of $3177.6 in Q3 2021, down 21.88% quarter-over-quarter from $4067.6 in Q2 2021, and up 323.45% on a YoY basis from $750.42 in Q3 2020.
IM Cannabis (IMCC) Research & Development (2020 - 2021) Analysis & Trends
IM Cannabis' Research & Development history runs 2 years deep, the most recent figure standing at $3177.6 for Q3 2021.
- In Q3 2021, Research & Development rose 323.45% year-over-year to $3177.6; the TTM figure through Sep 2021 stood at $8802.4 (changed N/A YoY), while the FY2020 annual figure was $101521.2, down 42.19% from the prior year.
- Research & Development was $3177.6 for Q3 2021 at IM Cannabis, down from $4067.6 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $77168.8 in Q2 2020 to a low of $750.42 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 222.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 180.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 138.20 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 934,363.43 |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 296.20 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 97.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 103.35 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 39.38 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 46.94 Mn |
| 10 | IM Cannabis | 57,090.22 | -728,264.31 | 1.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 3,177.64 |
| Jun 30, 2021 | 4,067.64 |
| Mar 31, 2021 | 790.10 |
| Dec 31, 2020 | 767.05 |
| Sep 30, 2020 | 750.42 |
| Jun 30, 2020 | 77,168.82 |
| Mar 31, 2020 | 20,139.15 |